Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.

from Answers from the Lab · host Mayo Clinic Laboratories

(00:31) Could you provide a little bit about yourself and your background? (02:04) Could you provide an overview of the chromosomal microarray assay? (05:49) Why should the chromosomal microarray assay be used over other available assays, such as FISH? (08:56) Does the chromosomal microarray provide good benefits in terms of gain of 7 and loss of 10, and EGFR amplification? (12:03) What's the value of utilizing the test alongside a neuro-specific NGS panel, such as Mayo Clinic Laboratories' NONCP panel? (17:20) How are the results used in patient care? (19:41)Is there anything else you feel it's important to highlight?

Episode metadata supplied by the publisher feed · Published Feb 21, 2023

Embed this episode

Attribution link and audio player

What this episode covers

Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray assay outperforms other tests for brain tumor analysis. The microarray aligns with the World Health Organization's latest classification of central nervous system tumors.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Chromosomal microarray better informs brain tumor diagnosis: Robert Jenkins, M.D., Ph.D.

0:00 23:57

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Answers from the Lab?

This episode is 23 minutes long.

When was this Answers from the Lab episode published?

This episode was published on February 21, 2023.

Can I download this Answers from the Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!